Calgary, AB; September 15, 2021: Two Canadian innovative genomics diagnostic companies, OncoHelix and Canexia Health, are partnering to help Canadian cancer patients gain access to precision genomic testing via their oncologist. Using a circulating tumour DNA (ctDNA) or “liquid biopsy” blood sample, the partnership allows for Canexia Health’s Follow It® ctDNA 38-gene panel to be accessed through OncoHelix for testing services at HTL lab, a clinically accredited, Canadian-based, genome diagnostics lab that can support test requests for all provinces in Canada. This is one of the first opportunities where Canadians have an alternative choice to out-of-country ctDNA cancer genomics panel and lab testing service providers.
Filomena Servidio-Italiano, President and CEO of Colorectal Cancer Resource & Action Network comments on what it will mean to have ctDNA genomic profiling available in Canada: “ctDNA results facilitated by OncoHelix using the Follow It panel can provide much needed insight for both patients and clinicians, giving way to the opportunity for personalizing treatment and ultimately improved patient outcomes. We encourage all Canadians diagnosed with metastatic colorectal cancer to speak to their treating oncologist about undergoing biomarker testing early on in their treatment journey to help inform treatment decisions.”
“Targeted cancer treatments can dramatically improve patient outcomes ,” said Michael Ball, CEO of Canexia Health. “Follow It is focused on such actionable results, including biomarkers associated with response to FDA and Health Canada approved therapies, as well as current Canadian clinical trials. We are pleased to offer Follow It through this collaboration with OncoHelix to provide Canadian cancer patients with a minimally invasive option for biomarker testing for multiple cancer types.”
The partnership between Canexia Health and OncoHelix will launch the Follow It® ctDNA panel in late September 2021 to all Canadian provinces. Requisition forms from oncologists will be accepted starting September 15, 2021 and can be found on the OncoHelix website at www.oncohelix.org.
OncoHelix’s mission is to facilitate exceptional clinical-grade molecular and immune profile testing for diagnostic, research, clinical trials and clinical use for patients and their oncologists. Based out of Calgary, Alberta Canada, OncoHelix works with health industry, patients and their oncologists to make cancer genomics and immune profiling accessible across all provinces in Canada and countries world-wide. OncoHelix is specialized in providing top line testing services with innovative panels, via a partnership with HTL Lab located within the University of Calgary.
Canexia Health makes high-quality genomic information accessible and affordable to support cancer treatment selection and monitoring. Our oncology software platform and clinical services enable actionable, cost-effective, and fast interpretation for next-generation sequencing assays.
Together with healthcare and diagnostic partners, we are leading the shift towards precision oncology.
For more information, please contact:
Director, Business Development
Head of Communications